Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | DEPEND: nivolumab with chemotherapy and response-stratified CRT in HNSCC

Ari Rosenberg, MD, University of Chicago, Chicago, IL, describes the trial design of the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). Patients, who a deep response i.e. a tumor shrinkage of more than 50%, received reduced chemoradiation, whereas patients with a suboptimal response received the standard dose. The primary endpoint was deep response rate. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.